|
A randomized open-label study of bortezomib, melphalan, and prednisone (VMP) versus daratumumab (DARA) plus VMP in patients with previously untreated multiple myeloma (MM) who are ineligible for high-dose therapy: 54767414MMY3007 (Alcyone). |
| |
|
Honoraria - Celgene; Janssen-Cilag |
Consulting or Advisory Role - Celgene; Janssen-Cilag; Onyx; Takeda |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Millennium; Novartis; Onyx; Sanofi; Skyline Diagnostics |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Millennium; Novartis; Onyx; Sanofi; Skyline Diagnostics |
Speakers' Bureau - Amgen; Celgene; Onyx |
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Karyopharm Therapeutics; Millennium; Novartis; Onyx; Sanofi; Skyline Diagnostics |
| |
|
Employment - Janssen Research & Development |
| |
|
Employment - Janssen Research & Development |
| |
|
Employment - Janssen Research & Development |
| |
|
Employment - Janssen Research & Development |
| |
|
Employment - Janssen Research & Development |
| |
|
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Millennium; Novartis; Onyx; Sanofi |
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Millennium; Novartis; Onyx; Sanofi |